Equity research analysts and Wall Street financial institutions maintain generally favorable twelve-month consensus price targets for Charles River Laboratories (CRL) stock, driven by expected stabilization in biopharmaceutical outsourcing demand and long-term growth in cell and gene therapy manufacturing. While short-term trading remains sensitive to pharmaceutical R&D funding cycles and broader macroeconomic pressures, fundamental analysts project steady mid-term appreciation based on the company's solid market leadership position.